Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16419854 | 1.00 | KDM4E (0.45) | KDM4EALDH1A1POLBTSHRTHRB | |
| SCHEMBL20235111 | 1.00 | KDM4E (0.45) | KDM4EALDH1A1POLBTSHRTHRB | |
| SCHEMBL12371251 | 1.00 | KDM4E (0.45) | KDM4EALDH1A1POLBTSHRTHRB | |
| SCHEMBL5611814 | 0.95 | KDM4E (0.41) | KDM4EALDH1A1POLBTSHRTHRB | |
| SCHEMBL22692193 | 0.91 | KDM4E (0.40) | KDM4EALDH1A1POLBTSHRTHRB | |
| SCHEMBL9541679 | 0.90 | KDM4E (0.45) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL14198320 | 0.90 | KDM4E (0.45) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL9540608 | 0.90 | KDM4E (0.45) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL9972442 | 0.88 | KDM4E (0.43) | KDM4EALDH1A1POLBTSHRTHRB | |
| SCHEMBL10330545 | 0.88 | KDM4E (0.43) | KDM4EALDH1A1POLBTSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660004-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | KDM4E 1037/4885ALDH1A1 4029/4885POLB 4324/4885 |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | KDM4E 1037/4885ALDH1A1 4029/4885POLB 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.